Atossa Therapeutics, Inc. (ATOS)

Market Cap	171.67M
Revenue (ttm)	n/a
Net Income (ttm)	-30.09M
Shares Out	125.30M
EPS (ttm)	-0.24
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,171,650
Open	1.430
Previous Close	1.420
Day's Range	1.330 - 1.430
52-Week Range	0.590 - 2.310
Beta	1.24
Analysts	Strong Buy
Price Target	4.50 (+228.47%)
Earnings Date	May 13, 2024

About ATOS

Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing medicines in the areas of unmet medical need in oncology. The company's lead program is Endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It is also developing AT-H201 for lung injury caused by cancer treatment. In addition, the company develops immunotherapy/chimeric antigen receptor therapy programs. It has a research agreement with Dana-Farber Cancer Institute, Inc. to support resea...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Nov 8, 2012
• Employees: 12
• Stock Exchange: NASDAQ
• Ticker Symbol: ATOS

Analyst Forecast

According to 2 analysts, the average rating for ATOS stock is "Strong Buy." The 12-month stock price forecast is $4.5, which is an increase of 228.47% from the latest price.

Price Target

$4.5

(228.47% upside)

Analyst Consensus: Strong Buy